AVR Key Statistics, Chart & Performance
The current stock price of AVR is 5.33 USD. In the past month the price increased by 41.53%.
AVR Latest News, Press Relases and Analysis
AVR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.56 | 213.10B | ||
| ISRG | INTUITIVE SURGICAL INC | 64.57 | 197.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.42 | 137.42B | ||
| SYK | STRYKER CORP | 26.86 | 135.30B | ||
| IDXX | IDEXX LABORATORIES INC | 55.66 | 56.04B | ||
| BDX | BECTON DICKINSON AND CO | 13.76 | 56.63B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.65 | 48.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.4 | 38.48B | ||
| RMD | RESMED INC | 25.4 | 36.71B | ||
| DXCM | DEXCOM INC | 36.32 | 26.35B | ||
| PODD | INSULET CORP | 64.59 | 20.77B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.51 | 18.45B |
Related stock screener links
About AVR
Company Profile
Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. The company is headquartered in Eagan, Minnesota and currently employs 136 full-time employees. The company went IPO on 2024-12-13. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Company Info
ANTERIS TECHNOLOGIES GLOBAL
860 Blue Gentian Road, Suite 340
Eagan MINNESOTA US
Employees: 136
Phone: 16514930606
ANTERIS TECHNOLOGIES GLOBAL / AVR FAQ
What does ANTERIS TECHNOLOGIES GLOBAL do?
Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. The company is headquartered in Eagan, Minnesota and currently employs 136 full-time employees. The company went IPO on 2024-12-13. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
What is the current price of AVR stock?
The current stock price of AVR is 5.33 USD. The price increased by 12.68% in the last trading session.
Does AVR stock pay dividends?
AVR does not pay a dividend.
How is the ChartMill rating for ANTERIS TECHNOLOGIES GLOBAL?
AVR has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ANTERIS TECHNOLOGIES GLOBAL (AVR) stock traded?
AVR stock is listed on the Nasdaq exchange.
Can you provide the market cap for ANTERIS TECHNOLOGIES GLOBAL?
ANTERIS TECHNOLOGIES GLOBAL (AVR) has a market capitalization of 219.60M USD. This makes AVR a Micro Cap stock.
When does ANTERIS TECHNOLOGIES GLOBAL (AVR) report earnings?
ANTERIS TECHNOLOGIES GLOBAL (AVR) will report earnings on 2026-03-09.
AVR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to AVR.
AVR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AVR. AVR has a bad profitability rating. Also its financial health evaluation is rather negative.
AVR Financial Highlights
Over the last trailing twelve months AVR reported a non-GAAP Earnings per Share(EPS) of -2.34. The EPS decreased by -65.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -440.09% | ||
| ROE | -2269.93% | ||
| Debt/Equity | 0.02 |
AVR Forecast & Estimates
8 analysts have analysed AVR and the average price target is 16.83 USD. This implies a price increase of 215.76% is expected in the next year compared to the current price of 5.33.
For the next year, analysts expect an EPS growth of 19.18% and a revenue growth -38.46% for AVR